An update on genetic aberrations in T-cell neoplasms.


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 14 08 2022
revised: 17 12 2022
accepted: 26 12 2022
pubmed: 22 2 2023
medline: 11 3 2023
entrez: 21 2 2023
Statut: ppublish

Résumé

T-cell neoplasms are a highly heterogeneous group of leukaemias and lymphomas that represent 10-15% of all lymphoid neoplasms. Traditionally, our understanding of T-cell leukaemias and lymphomas has lagged behind that of B-cell neoplasms, in part due to their rarity. However, recent advances in our understanding of T-cell differentiation, based on gene expression and mutation profiling and other high throughput methods, have better elucidated the pathogenetic mechanisms of T-cell leukaemias and lymphomas. In this review, we provide an overview of many of the molecular abnormalities that occur in various types of T-cell leukaemia and lymphoma. Much of this knowledge has been used to refine diagnostic criteria that has been included in the fifth edition of the World Health Organization. This knowledge is also being used to improve prognostication and identify novel therapeutic targets, and we expect this progress will continue, eventually resulting in improved outcomes for patients with T-cell leukaemias and lymphomas.

Identifiants

pubmed: 36801152
pii: S0031-3025(23)00027-2
doi: 10.1016/j.pathol.2022.12.350
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

287-301

Informations de copyright

Copyright © 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

Megan Parilla (M)

Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, IL, USA; Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, IL, USA.

Andres E Quesada (AE)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aquesada@mdanderson.org.

L Jeffrey Medeiros (LJ)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Beenu Thakral (B)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: bthakral@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH